VistaGen Therapeutics (VTGN)
(Delayed Data from NSDQ)
$2.97 USD
+0.05 (1.71%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $2.96 -0.01 (-0.34%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Fundamental Charts
About Market Cap
As of the previous market close, VistaGen Therapeutics, Inc. has a market cap of $87.19M, which represents its share price of $2.92 multiplied by its outstanding shares number of 29.86M. As a small-cap company, VTGN's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
VTGN 2.97 +0.05(1.71%)
Will VTGN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for VTGN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VTGN
Exact Sciences (EXAS) Surpasses Q2 Earnings and Revenue Estimates
Inovio Pharmaceuticals (INO) Expected to Beat Earnings Estimates: Should You Buy?
VTGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Opus Genetics, Inc. (IRD) Reports Q1 Loss, Tops Revenue Estimates
Clearside Biomedical, Inc. (CLSD) Reports Q1 Loss, Tops Revenue Estimates
Seer, Inc. (SEER) Reports Q1 Loss, Tops Revenue Estimates
Other News for VTGN
Vistagen to Report Fiscal Year 2026 First Quarter Results and Host Corporate Update Conference ...
Vistagen to Present at the BTIG Virtual Biotechnology Conference | VTGN Stock News
Vistagen Honored for Outstanding Workplace Culture and Mental Health Leadership | VTGN Stock News
Vistagen (VTGN) Appoints Elissa Cote as Chief Corporate Development Officer | VTGN Stock News
Vistagen appoints Elissa Cote as Chief Corporate Development Officer